natgillin/translations-raw huggingface dataset:
The choice of the infusion duration should be made by the treating physician considering the frequency of the infusion bag changes.
Trajanje infundiranja določi lečeči zdravnik ob upoštevanju pogostnosti menjav infuzijskih vrečk.
The choice of this fixed combination should be based not only on potential adherence criteria, but mainly on expected efficacy and risk related to the three nucleoside analogues.
Izbira te fiksne kombinacije ne sme temeljiti le na rutini, ampak predvsem na pričakovani učinkovitosti in tveganjih, ki jih prinaša kombinacija teh treh nukleozidnih analogov.
The cholesterol drawn out of the blood in this way is the LDL, or ‘bad’ cholesterol.
Holesterol, ki se iz krvi odstrani na tak način, je holesterol LDL ali „slabi“ holesterol.
The cholesterol drawn out of the blood in this way is the ‘bad’ cholesterol.
Holesterol, ki se na tak način odstrani iz krvi, je „slabi“ holesterol.
The cholic acid contained in Kolbam replaces the patient’s missing cholic acid.
Holna kislina, ki jo vsebuje zdravilo Kolbam, nadomesti holno kislino, ki je primanjkuje bolniku.
The cholic acid contained in Orphacol replaces the patient’s missing cholic acid.
Holna kislina v zdravilu Orphacol nadomesti manjkajočo holno kislino pri bolniku.
The cholic acid dose for patients with familial hypertriglyceridaemia will have to be established and adjusted as necessary, an elevated dose may be required in order to suppress urinary bile acids (see section 4.4)
Pri bolnikih z družinsko hipertrigliceridemijo je treba določiti odmerek holne kisline in ga po potrebi prilagoditi; morda bo za zaviranje žolčnih kislin v urinu potreben povečan odmerek (glejte poglavje 4.4).
The choriogonadotropin alfa in Ovitrelle is produced by a method known as ‘recombinant DNA technology’: it is made by a cell that has received a gene (DNA), which makes cell able to produce it.
„tehnologija rekombinantne DNK“: izdela ga celica, ki je prejela gen (DNK), s katerim lahko tvori horiogonadotropin alfa.
The Chromogenic Factor Xa Assay, the Thrombin Time (TT) assay and the assays used for the diagnosis of Heparin Induced Thrombocytopenia (HIT) are not affected by oritavancin.
Oritavancin ne vpliva na kromogeni preizkus določanja aktivnosti faktorja Xa, določanje trombinskega časa (TT) in preizkus trombocitopenije, izzvane s heparinom (HIT).
The Chromogenic Factor Xa Assay, the Thrombin Time (TT) assay and the assays used for the diagnosis of Heparin Induced Thrombocytopenia (HIT) are not affected by oritavancin.
Oritavancin ne vpliva na kromogeni preizkus določanja aktivnosti faktorja Xa, določanje trombinskega časa (TT, thrombin Time) in preizkus trombocitopenije, izzvane s heparinom (HIT, heparin induced thrombocytopenia).
The CIDP study was performed with 28 patients.
Študija CIDP je bila opravljena pri 28 bolnikih.
The CL/F of ustekinumab was not impacted by gender.
Če se ti simptomi pojavijo je treba uvesti ustrezno zdravljenje.
The CLcr in ml/min may be estimated from serum creatinine (mg/dl) determination, for adults and adolescents weighing 50 kg or more, using the following formula:
CLcr v ml/min je pri odraslih in mladostnikih, s telesno maso 50 kg in več, mogoče oceniti iz koncentracije kreatinina v serumu (mg/dl) po formuli:
The CLcr in ml/min may be estimated from serum creatinine (mg/dl) determination, for adults and adolescents weighting 50 kg or more, using the following formula:
CLcr v ml/min je pri odraslih in mladostnikih, s telesno maso 50 kg in več, mogoče oceniti iz koncentracije kreatinina v serumu (mg/dl) po formuli:
The CLcr in ml/min/1.73 m2 may be estimated from serum creatinine (mg/dl) determination using, for young adolescents and children using the following formula (Schwartz formula):
CLcr v ml/min/1,73 m2 je pri mlajših mladostnikih, otrocih in dojenčkih mogoče oceniti iz koncentracije kreatinina v serumu (mg/dl) z uporabo naslednje formule (po Schwartzevi formuli):
The CLcr in ml/min/1.73 m2 may be estimated from serum creatinine (mg/dl) determination, for young adolescents and children using the following formula (Schwartz formula):
CLcr v ml/min/1,73 m2 je pri mlajših mladostnikih, otrocih in dojenčkih, mogoče oceniti iz koncentracije kreatinina v serumu (mg/dl) z uporabo naslednje formule (po Schwartzevi formuli):
The CLcr in ml/min/1.73 m2 may be estimated from serum creatinine (mg/dl) determination, for young adolescents, children and infants, using the following formula (Schwartz formula):
CLcr v ml/min/1,73 m2 je pri mlajših mladostnikih, otrocih in dojenčkih, mogoče oceniti iz koncentracije kreatinina v serumu (mg/dl) z uporabo naslednje formule (po Schwartzevi formuli):
The cleansing gel for Qutenza contains butylhydroxyanisole which may cause local skin reactions (e.g. contact dermatitis), or irritation of the eyes and mucous membranes.
Čistilni gel za zdravilo Qutenza vsebuje butilhidroksianizol, ki lahko povzroči lokalne kožne reakcije (npr. kontaktni dermatitis) ali draženje oči in sluznic.
The cleansing gel for Qutenza contains butylhydroxyanisole, which may cause local skin reactions (e.g. contact dermatitis) or irritation of the eyes and mucous membranes.
Čistilni gel za zdravilo Qutenza vsebuje butilhidroksianizol, ki lahko povzroča lokalne kožne reakcije (npr. kontaktni dermatitis) ali draženje oči in sluznic.
The clear and colourless solution is contained in a glass cartridge.
Bistra in brezbarvna raztopina je v steklenem vložku.
The clear and colourless solution is contained in a glass vial with 1 injection syringe, 1 injection needle and 1 cleansing swab.
Bistra in brezbarvna raztopina je v stekleni viali z 1 injekcijsko brizgo, 1 injekcijsko iglo in 1 čistilnim tamponom.
The clear and colourless solution is contained in a glass with 1 injection syringe, 1 injection needle and 1 cleansing swab.
Bistra in brezbarvna raztopina je v stekleni viali z 1 injekcijsko brizgo, 1 injekcijsko iglo in 1 čistilnim tamponom.
The clear plastic plunger rod MUST always be attached first before breaking the white tip off of the pre-filled water syringe.
Prozorno plastično držalo bata MORATE vedno namestiti prej, preden odlomite belo konico z napolnjene injekcijske brizge z vodo.
The clear, reconstituted solution is yellow to yellow-green in colour and provides 1 mg per ml of topotecan.
Pripravljena raztopina je bistra, rumene do rumene-zelene barve in vsebuje 1 mg topotekana na ml.
The clearance and volume of distribution of Soliris are weight dependent, which forms the basis for a weight categorical based dose regimen in paediatric patients (see section 4.2)..
Očistek in porazdelitveni prostor zdravila Soliris sta odvisna od telesne mase, ki pri pediatričnih bolnikih predstavlja podlago za shemo odmerjanja na temelju kategorij telesne mase (glejte poglavje 4.2).
The clearance of bazedoxifene is 0.4 ±0.1 L/h/kg based on IV administration.
Očistek bazedoksifena po intravenski uporabi je 0,4 ± 0,1 l/h/kg.
The clearance of pembrolizumab increased with increasing body weight; resulting exposure differences are adequately addressed by administration on a mg/kg basis.
Očistek pembrolizumaba se je povečeval z naraščanjem telesne mase, a nastale razlike v izpostavljenosti ustrezno odtehta uporaba na podlagi mg/kg.
The clearance of sirolimus may be reduced in patients with impaired hepatic function (see section 5.2).
Očistek sirolimusa utegne biti pri bolnikih z okvarjeno jetrno funkcijo zmanjšan (glejte poglavje 5.2).
The clinical
Klinični izid
The clinical benefit of apremilast was also demonstrated regardless of prior psoriasis medication usage and response to prior psoriasis treatments.
Klinična koristnost apremilasta je bila dokazana tudi ne glede na predhodno uporabo zdravil za psoriazo in odziv na predhodna zdravila za psoriazo.
The clinical benefit of apremilast was demonstrated across multiple subgroups defined by baseline demographics and baseline clinical disease characteristics (including psoriasis disease duration and patients with a history of psoriatic arthritis).
Klinično koristnost apremilasta so prikazali v več podskupinah, opredeljenih z izhodiščnimi demografskimi parametri in izhodiščnimi značilnostmi klinične bolezni (vključno s trajanjem bolezni psoriaze in bolniki z anamnezo psoriatičnega artritisa).
The clinical benefit of dabigatran with regard to stroke and SEE prevention and decreased risk of ICH compared to warfarin is preserved across individual subgroups, e.g. renal impairment, age, concomitant medication use such as anti-platelets or P-gp inhibitors.
Klinična korist zdravljenja z dabigatranom ostaja nespremenjena pri preprečitvi možganske kapi in sistemskih emboličnih dogodkov ter zmanjšanju tveganja intrakranialne krvavitve v primerjavi z varfarinom v posameznih podskupinah z boleznimi, kot so: ledvična okvara, starost, sočasna zdravila, na primer protitrombocitna zdravila ali zaviralci P-gp.
The clinical benefit of YENTREVE compared with placebo has not been demonstrated in women with mild SUI, defined in randomised trials as those with IEF < 14 per week.
Klinične koristi zdravila YENTREVE v primerjavi s placebom pri bolnicah z blago SUI, definirano tako v randomiziranih preskušanjih kot tistih z IEF < 14 na teden, niso dokazali.
The clinical consequences of the inhibition are not known.
Klinične posledice zaviranja niso znane.
The clinical consequences of the inhibition of the metabolism of bupropion via CYP2B6 enzyme and the consequent changes in the bupropion-hydroxybupropion ratio are currently unknown, but could potentially lead to reduced efficacy of naltrexone / bupropion.
Klinične posledice zaviranja presnove bupropiona prek encima CYP2B6 in posledične spremembe razmerja bupropion : hidroksibupropion še niso znane, vendar bi lahko povzročilo zmanjšano učinkovitost naltreksona/bupropiona.
The clinical consequences of the lower post-primary and post-booster immune responses observed after the two-dose primary schedule are not known.
Klinične posledice manjšega poprimarnega in poobnovitvenega imunskega odziva po primarnem razporedu z dvema odmerkoma niso znane.
The clinical data are limited and an increased risk of cutaneous reactions in patients with a history of NNRTI-associated cutaneous reaction cannot be excluded (see section 4.4).
Klinični podatki so omejeni in povečanega tveganja za pojav kožnih reakcij pri bolnikih, ki so imeli v anamnezi kožne reakcije, povezane z jemanjem NNRTI, ni mogoče izključiti (glejte poglavje 4.4).
The clinical data obtained in patients with Sickle Cell Syndrome have not shown evidence of adverse reactions of hydroxycarbamide on hepatic and renal function.
Klinični podatki, zbrani pri bolnikih s srpasto celičnim sindromom, ne kažejo dokazov o neželenih reakcijah hidroksikarbamida na jetrno in ledvično funkcijo.
The clinical data obtained in patients with Sickle Cell Syndrome have not shown evidence of adverse reactions of hydroxycarbamide on hepatic and renal function.
Klinični podatki, zbrani pri bolnikih s srpasto celičnim sindromom, ne kažejo dokazov o neželenih učinkih hidroksikarbamida na jetrno in ledvično funkcijo.
The clinical data to support the use of Sovaldi in patients with genotype 5 and 6 HCV infection is very limited (see section 5.1).
Klinični podatki, ki bi podprli uporabo zdravila Sovaldi pri bolnikih z okužbo s HCV genotipa 5 in 6, so zelo omejeni (glejte poglavje 5.1).
The clinical development programme included 2,354 patients who received umeclidinium/vilanterol once daily in the Phase III clinical studies of 24 weeks or more, of whom 1,296 patients received the recommended dose of 55/22 micrograms in 24-week studies, 832 patients received a higher dose of 113/22 micrograms in 24-week studies and 226 patients received 113/22 micrograms in a 12-month study.
Program kliničnega razvojavključuje 2.354 bolnikov, ki so dobivali kombinacijo umeklidinij/vilanterol enkrat dnevno v kliničnih študijah III. faze, ki so trajale 24 tednov ali več; od teh je 1.296 bolnikov dobivalo priporočeni odmerek 55/22 mikrogramov v 24-tedenskih študijah, 832 bolnikov je dobivalo višji odmerek 113/22 mikrogramov v 24-tedenskih študijah, 226 bolnikov pa je dobivalo 113/22 mikrogramov v eni 12-mesečni študiji.
The clinical effect of the decreased exposure has not been formally assessed but it is likely to be clinically significant.
Kliničnega pomena zmanjšane izpostavljenosti niso formalno preiskovali, verjetno pa je klinično pomembna.
The clinical effect of this dose adjustment has not been adequately
učinek take prilagoditve odmerka
The clinical efficacy and safety of DARZALEX for the treatment of patients with relapsed and refractory multiple myeloma was demonstrated in two open-label studies.
Klinično učinkovitost in varnost zdravila DARZALEX pri zdravljenju bolnikov s ponovljenim in neodzivnim diseminiranim plazmocitomom, so dokazali v dveh odprtih študijah.
The clinical efficacy and safety of Galafold have been evaluated in two Phase 3 pivotal trials and an open-label extension (OLE) trial.
Klinična učinkovitost in varnost zdravila Galafold sta bili ocenjeni v dveh ključnih preskušanjih faze 3 in v odprtem podaljšanem preskušanju.
The clinical efficacy and safety of Lonsurf were evaluated in an international, randomised, double- blind, placebo-controlled Phase III study (RECOURSE) in patients with previously treated metastatic colorectal cancer.
Klinično učinkovitost in varnost zdravila Lonsurf so ovrednotili v mednarodni, randomizirani, dvojno slepi, s placebom kontrolirani študiji III. faze (RECOURSE) pri bolnikih z metastatskim kolorektalnim rakom, ki so bili predhodno že zdravljeni.
The clinical efficacy and safety of ospemifene was determined primarily from two multi-centre, placebo-controlled trials of 12 weeks duration (Trials 1 and 2) and a third long-term safety trial of 52 weeks duration (Trial 3) in post-menopausal patients with vulvar and vaginal atrophy (VVA).
Klinična učinkovitost in varnost ospemifena sta bili prvenstveno ugotovljeni v dveh multicentričnih, s placebom kontroliranih preskušanjih, ki sta trajali 12 tednov (preskušanje 1 in 2) in v tretjem dolgoročnem preskušanju varnosti, ki je trajalo 52 tednov (preskušanje 3) pri bolnicah po menopavzi z atrofijo vulve in vagine (VVA).
The clinical efficacy and safety of Stivarga have been evaluated in an international, multi-center, randomized, double-blind, placebo-controlled phase III study (GRID) in patients with gastrointestinal stromal tumors (GIST) previously treated with 2 tyrosine kinase inhibitors (imatinib and sunitinib).
Klinično učinkovitost in varnost zdravila Stivarga so ovrednotili v mednarodnem, multicentričnem, randomiziranem, dvojno slepem, s placebom nadzorovanem kliničnem preskušanju III. faze (GRID) pri bolnikih z gastrointestinalnimi stromalnimi tumorji (GIST), ki so jih predhodno zdravili z dvema zaviralcema tirozin kinaze (imatinibom in sunitinibom).
The clinical efficacy in study AUX-CC- 862 was similar to that reported in studies CORD I and CORD II.
Klinična učinkovitost v študiji AUX-CC-862 je bila podobna tisti, o kateri so poročali v študijah CORD I in CORD II.
The clinical efficacy of Incruse administered once daily was evaluated in 904 adult patients who received umeclidinium bromide or placebo from two pivotal Phase III clinical studies with a clinical diagnosis of COPD; a 12-week study (AC4115408) and a 24-week study (DB2113373).
Klinično učinkovitost zdravila Incruse enkrat na dan so ocenili pri 904 odraslih bolnikih s klinično diagnozo KOPB, ki so prejemali umeklidinijev bromid ali placebo v dveh ključnih kliničnih študijah III. faze: v 12- tedenski študiji (AC4115408) in 24-tedenski študiji (DB2113373).
The clinical efficacy of maraviroc (in combination with other antiretroviral medicinal products) on plasma HIV RNA levels and CD4+ cell counts have been investigated in two pivotal ongoing, randomized, double blind, multicentre studies (MOTIVATE 1 and MOTIVATE 2, n=1076 ) in patients infected with CCR5 tropic HIV-1 as determined by the Monogram Trofile Assay.
Klinično učinkovitost delovanja maraviroka (v kombinaciji z drugimi protiretrovirusnimi zdravili) na raven HIV RNA v plazmi in število celic CD4+ so raziskali v dveh ključnih, še potekajočih randomiziranih dvojno slepih multicentričnih študijah (MOTIVATE 1 in MOTIVATE 2, n = 1076 ) pri bolnikih, okuženih s CCR5-tropnim HIV-1 (ugotovljeno z Monogramovim preskusom Trofile).
The clinical efficacy of Viramune prolonged-release is based on 48-week data from a randomised, double-blind, double-dummy phase 3 study (VERxVE – study 1100.1486) in treatment-naïve patients and on 24-week data from a randomised, open-label study in patients who transitioned from Viramune immediate-release tablets administered twice daily to Viramune prolonged-release tablets administered once daily (TRANxITION – study 1100.1526).
Klinična učinkovitost zdravila Viramune s podaljšanim sproščanjem temelji na podatkih, ki so jih pridobili v 48 tednih dvojno slepe študije 3. faze z dvojnim placebom pri naključno izbranih še nezdravljenih bolnikih (VERxVE – študija 1100.1486) in na podatkih, ki so jih zbrali v 24 tednih odprte študije pri naključno izbranih bolnikih, ki so zamenjali zdravilo Viramune tablete s takojšnjim sproščanjem, katere so jemali dvakrat na dan, z zdravilom Viramune tablete s podaljšanim sproščanjem, ki jih jemljejo enkrat na dan (TRANxITION – študija 1100.1526).
The clinical evidence for the effect of Zontivity in patients with a history of myocardial infarction, defined as a spontaneous MI ≥2 weeks but 12 months prior, is derived from TRA 2°P - TIMI 50 (Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events).
Klinični dokaz učinka zdravila Zontivity pri bolnikih z anamnezo MI, definiranega kot spontani MI ≥ 2 tedna, toda  12 mesecev prej, izhaja iz študije TRA 2°P – TIMI 50 (Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events).
The clinical evidence for the efficacy and safety of ticagrelor is derived from two phase 3 trials:
Klinični dokazi o učinkovitosti in varnosti ticagrelorja izvirajo iz dveh preskušanj 3. faze:
The clinical experience in other species is very limited (Lichtheimia spp. n=2, Cunninghamella spp. n=1, Actinomucor elegans n=1).
Klinične izkušnje pri drugih vrstah so zelo omejene (Lichtheimia spp. n = 2, Cunninghamella spp. n = 1, Actinomucor elegans n = 1).
The clinical experience in patients > 75 years is very limited (see section 5.2).
Kliničnih izkušenj pri bolnikih > 75 let je zelo malo (glejte poglavje 5.2).
The clinical experience in patients >75 years is very limited (see section 5.2).
Kliničnih izkušenj z bolniki, starimi ≥ 75 let, je zelo malo (glejte poglavje 5.2).
The clinical experience in patients with moderate renal impairment is very limited and the use of prolonged-release exenatide is not recommended.
Kliničnih izkušenj pri bolnikih z zmerno okvaro ledvic je zelo malo, zato uporaba eksenatida v obliki s podaljšanim sproščanjem ni priporočljiva.
The clinical experience of MabThera subcutaneous formulation in Non-Hodgkin’s lymphoma is based on data from a phase III clinical trial (SABRINA BO22334) in patients with follicular lymphoma (FL) and a phase Ib dose-finding/dose-confirmation trial (SparkThera BP22333) in patients with FL.
Klinične izkušnje s podkožno obliko zdravila MabThera pri ne-Hodgkinovem limfomu temeljijo na podatkih kliničnega preskušanja III. faze (SABRINA, BO22334) pri bolnikih s folikularnimi limfomi in preskušanja faze Ib za določanje/potrditev odmerka (SparkThera, BP22333) pri bolnikih s folikularnimi limfomi.
The clinical experience reported in the literature is from a patient population with inborn deficiency of 3β-Hydroxy-Δ5-C27-steroid oxidoreductase or Δ4-3-Oxosteroid-5β-reductase that includes principally infants from the age of one month, children and adolescents.
V literaturi objavljene klinične izkušnje izvirajo iz populacije bolnikov s prirojenim pomanjkanjem 3β-hidroksi-Δ5-C27-steroid-oksidoreduktaze ali Δ4-3-oksosteroid-5β-reduktaze, ki v glavnem zajema dojenčke po enem mesecu starosti, otroke in mladostnike.
The clinical implication of these findings has not been demonstrated.
Klinična implikacija teh izsledkov trenutno ni znana.
The clinical implications of the differences in effect on PRA are not known at the present time.
Klinični pomen drugačnega učinka na aktivnost renina v plazmi zaenkrat ni znan.
The clinical implications of this finding are currently unknown.
Klinična implikacija tega izsledka trenutno ni znana.
The clinical Phase III development programme included two phase III studies: a 6-month placebo-controlled study and a 12-month placebo and active-controlled (open label tiotropium
Program kliničnih študij faze III je vključeval dve študiji faze III: 6-mesečno študijo, kontrolirano s placebom, in 12-mesečno študijo, kontrolirano s placebom in aktivno (odprto uporabljen tiotropij v odmerku 18 mikrogramov enkrat na dan).
The clinical presentation of Pompe disease can be described as a spectrum of disease which ranges from a rapidly-progressing infantile-onset form (onset of symptoms of Pompe disease typically within the first year of life and a very short expected life-span) to a less rapidly-progressing late-onset form.
Klinično predstavitev Pompejeve bolezni je mogoče opisati kot spekter bolezni, ki sega od hitro- napredujoče oblike z zgodnjim nastopom (nastop simptomov Pompejeve bolezni običajno v prvem letu življenja in zelo kratka pričakovana življenjska doba), do manj hitro-napredujoče oblike s poznim nastopom.
The clinical program (AMPLIFY: apixaban versus enoxaparin/warfarin, AMPLIFY-EXT: apixaban versus placebo) was designed to demonstrate the efficacy and safety of apixaban for the treatment of DVT and/or PE (AMPLIFY), and extended therapy for the prevention of recurrent DVT and/or PE following 6 to 12 months of anticoagulant treatment for DVT and/or PE (AMPLIFY-EXT).
Zasnovan je bil klinični program (AMPLIFY: primerjava apiksabana in enoksaparina/varfarina, AMPLIFY-EXT: primerjava apiksabana in placeba) za dokazovanje učinkovitosti in varnosti apiksabana pri zdravljenju GVT in/ali PE (AMPLIFY) ter pri podaljšanem zdravljenju za preprečevanje ponovitve GVT in/ali PE, ki je sledilo od 6- do 12-mesečnemu antikoagulacijskemu zdravljenju GVT in/ali PE (AMPLIFY-EXT).
The clinical programme for Savene (dexrazoxane) included two open, single-arm, multicentre studies.
Klinični program za zdravilo Savene (deksrazoksan) je obsegal dve odprti multicentrični študiji brez primerjalne skupine.
The clinical protection of the pertussis component of Infanrix, against WHO-defined typical pertussis ( 21 days of paroxysmal cough) was demonstrated after 3-dose primary immunisation in the studies tabulated below:
Klinična zaščita s sestavino pertusis cepiva Infanrix proti značilnemu oslovskemu kašlju v skladu z definicijo Svetovne zdravstvene organizacije (napadi kašlja, ki trajajo  21 dni) je bila dokazana po primarni imunizaciji s 3 odmerki v študijah, prikazanih v spodnji preglednici:
The clinical protection of the pertussis component of Infanrix, against WHO-defined typical pertussis ( 21 days of paroxysmal cough) was demonstrated in:
Klinično je bila zaščita pertusisne sestavine cepiva Infanrix proti značilnemu oslovskemu kašlju v skladu z definicijo WHO (napadi kašlja, ki trajajo ≥ 21 dni) prikazana v:
The clinical relevance of
Klinični pomen zmanjšanja
The clinical relevance of HACA formation in MabThera-treated patients is unclear.
Klinični pomen pojava HACA pri bolnikih, zdravljenih z zdravilom MabThera, ni jasen.
The clinical relevance of reduced in vitro susceptibility to lopinavir has been examined by assessing the virologic response to Kaletra therapy, with respect to baseline viral genotype and phenotype, in 56 patients previous failing therapy with multiple protease inhibitors.
Klinični pomen zmanjšane občutljivosti za lopinavir in vitro so raziskali z oceno virološkega odziva na zdravljenje z zdravilom Kaletra (upoštevaje izhodiščni virusni genotip in fenotip) pri 56 bolnikih s predhodno neuspešnim zdravljenjem z več zaviralci proteaz.
The clinical relevance of such findings remains, however, not well defined.
Klinični pomen takšnih izsledkov ostaja slabo opredeljen.